This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
AstraZeneca has terminated all development of vemircopan, the oral factor D inhi...
We’re in dealmaking season for publicly traded digital health companies. In ...
Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech f...
A trade group representing 1,600 hospitals says 340B rebate models proposed by m...
The shift to a VBC model represents more than an evolution in healthcare deliver...
Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage met...
Currently available therapies for Hunter syndrome don’t cross the blood-brain ba...
Regulators will have their work cut out for them under a new administration that...
Novo Nordisk’s monlunabant showed signs of neuropsychiatric side effects in a mi...
Little Otter’s $9.5 million fundraise included participation from Pivotal Ventur...
Supernus Pharmaceuticals’ Onapgo provides a continuous infusion of apomorphine t...
Carrot Fertility’s new menopause and midlife health clinic, called Telemedicine ...
LLMs, with their remarkable conversational abilities, are uniquely positioned to...
CMS recently issued a statement saying that it’s continuing the Medicare Drug Pr...
Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug p...
The healthcare industry is caught in the crosshairs of historical inflation, dri...